Takai Erina, Yachida Shinichi, Shimizu Kyoko, Furuse Junji, Kubo Emi, Ohmoto Akihiro, Suzuki Masami, Hruban Ralph H, Okusaka Takuji, Morizane Chigusa, Furukawa Toru
Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan.
Department of Gastroenterology, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
Oncotarget. 2016 Nov 8;7(45):74227-74235. doi: 10.18632/oncotarget.12490.
Clinicopathologic and genetic features of familial pancreatic cancer (FPC) in Asian countries remain largely unknown. The main purpose of this study was to determine the prevalence of FPC and to define causative FPC-predisposition genes in a Japanese cohort with pancreatic ductal adenocarcinoma (PDAC).We reviewed 1,197 patients with a pathologically proven PDAC and found that 88 (7.3%) were FPC patients who had at least one first-degree relative with PDAC. There were no significant differences between the FPC cases and sporadic cases in terms of gender, age, tumor location, stage, family history of any cancer except PDAC, and personal history of smoking, other cancers, diabetes mellitus and chronic pancreatitis. In the FPC patients, we then investigated the prevalence of germline mutations in 21 genes associated with hereditary predispositions for pancreatic, breast and ovarian cancers by means of the next-generation sequencing using a custom multiple-gene panel. We found that eight (14.5%) of the 54 FPC patients with available germline DNA carried deleterious mutations in BRCA2, PALB2, ATM, or MLH1. These results indicate that a significant fraction of patients with PDAC in Japan have a family history of pancreatic cancer, and some of them harbor deleterious causative mutations in known FPC predisposition genes.
亚洲国家家族性胰腺癌(FPC)的临床病理和遗传特征在很大程度上仍不为人知。本研究的主要目的是确定日本胰腺导管腺癌(PDAC)队列中FPC的患病率,并明确导致FPC的易感基因。我们回顾了1197例经病理证实为PDAC的患者,发现88例(7.3%)为FPC患者,他们至少有一位患PDAC的一级亲属。FPC病例与散发病例在性别、年龄、肿瘤位置、分期、除PDAC外的任何癌症家族史以及吸烟、其他癌症、糖尿病和慢性胰腺炎个人史方面均无显著差异。然后,我们对FPC患者采用定制的多基因检测板,通过下一代测序研究了21个与胰腺癌、乳腺癌和卵巢癌遗传易感性相关基因的种系突变患病率。我们发现,在54例有可用种系DNA的FPC患者中,有8例(14.5%)在BRCA2、PALB2、ATM或MLH1中携带有害突变。这些结果表明,日本相当一部分PDAC患者有胰腺癌家族史,其中一些人在已知的FPC易感基因中携带有害的致病突变。